Premium
Human granulocyte–macrophage colony‐stimulating factor DNA cationic‐lipid complexed autologous tumour cell vaccination in the treatment of canine B‐cell multicentric lymphoma
Author(s) -
Turek M. M.,
Thamm D. H.,
Mitzey A.,
Kurzman I. D.,
Huelsmeyer M. K.,
Dubielzig R. R.,
Vail D. M.
Publication year - 2007
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2007.00128.x
Subject(s) - granulocyte macrophage colony stimulating factor , lymphoma , granulocyte , cancer research , immunology , colony stimulating factor , medicine , macrophage , vaccination , chemistry , biology , haematopoiesis , in vitro , biochemistry , cytokine , microbiology and biotechnology , stem cell
This study describes the development of an human granulocyte–macrophage colony‐stimulating factor DNA cationic‐lipid complexed autologous tumour cell vaccine (hGM‐CSF CLDC ATCV) and its implementation, following a chemotherapy treatment protocol, in a randomized, placebo‐controlled, double‐blinded clinical trial in pet dogs with naturally occurring lymphoma. We hypothesized that the use of this vaccine would result in an antitumour immune response leading to improved first remission duration and overall survival in dogs with B‐cell lymphoma when compared with chemotherapy alone. Immune stimulation generated by hGM‐CSF CLDC ATCV was assessed by means of surrogate in vivo analysis (delayed‐type hypersensitivity [DTH]) as well as an ex vivo cellular assay (lymphocyte proliferation assay). The vaccine approach considered in the current report did not result in clinically improved outcomes. A small measure of immunomodulation was documented by DTH and several modifications to the approach are suggested. This report illustrates the feasibility of clinical trials with vaccine strategies using companion animals with non‐Hodgkin’s lymphoma.